Abstract

ObjectiveTo evaluate the performance of clinical criteria for predicting late treatment failure in patients with early non-response to certolizumab pegol (CZP).MethodsA protocol-specified analysis of interim data from ECLAIR, a 3-year...

Full Text

Published Version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB0238 USEFULNESS OF RAPID3 IN ASSESSING UNMET NEEDS OF RHEUMATOID ARTHRITIS PATIENTS FROM THE T-FLAG STUDY
M Suzuki ... S Imagama
Annals of the Rheumatic Diseases | VOL. 82
M Suzuki, et. al.M Suzuki ... S Imagama
30 May 2023
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Michael E Weinblatt ... Maurizio Cutolo
Arthritis research & therapy | VOL. 17
Michael E Weinblatt, et. al.Michael E Weinblatt ... Maurizio Cutolo
15 Nov 2015
AB0320 Patient-assessed disease activity score (PDAS) corresponds to standard disease statuses and response criteria defined by disease activity score 28 (DAS28) and clinical disease activity index (CDAI)
M.-H.A Leung ... D Farewell
Annals of the Rheumatic Diseases | VOL. 71
M.-H.A Leung, et. al.M.-H.A Leung ... D Farewell
01 Jun 2013
THU0065 Potential Predictors for Achieving and/or Maintaining Low Disease Activity or Remission in Patients with Rheumatoid Arthritis
N Akkoc ... D Karateev
Annals of the Rheumatic Diseases | VOL. 75
N Akkoc, et. al.N Akkoc ... D Karateev
01 Jun 2016
View more papers

More From: RMD Open

Paper Title
Journal
Date
Author
Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature
Teresa Grohmann ... Oliver Fitzgerald
RMD Open | VOL. 10
Teresa Grohmann, et. al.Teresa Grohmann ... Oliver Fitzgerald
12 Dec 2024
Correction: Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus
-
RMD Open | VOL. 10
--
12 Dec 2024
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
Iain B Mcinnes ... Laura C Coates
RMD Open | VOL. 10
Iain B Mcinnes, et. al.Iain B Mcinnes ... Laura C Coates
12 Dec 2024
Correction: comparison of active tuberculosis occurrence associated with janus kinase inhibitors and biological DMARDs in rheumatoid arthritis
-
RMD Open | VOL. 10
--
12 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.